Welcome to PracticeUpdate! We hope you are enjoying access to a selection of our top-read and most recent articles. Please register today for a free account and gain full access to all of our expert-selected content.
Already Have An Account? Log in Now
Efficacy and Safety of Tirzepatide, GLP-1 Receptor Agonists, and Other Weight Loss Drugs in Overweight and Obesity
abstract
This abstract is available on the publisher's site.
Access this abstract nowOBJECTIVE
This network meta-analysis evaluates the efficacy and safety of tirzepatide compared to glucagon-like peptide-1 receptor agonists (GLP-1 RA) and other weight loss drugs in the treatment of overweight and obesity.
METHODS
MEDLINE, Embase, and Cochrane CENTRAL were searched for randomized controlled trials on tirzepatide, GLP-1 RA, and weight loss drugs approved by the US Food and Drug Administration. A network meta-analysis was performed, drawing direct and indirect comparisons between treatment groups. Network diagrams and surface under the cumulative ranking curve analysis were performed for primary (≥5%, ≥10%, ≥15%, absolute weight loss) and secondary outcomes and adverse effects.
RESULTS
Thirty-one randomized controlled trials, involving more than 35,000 patients, were included in this study. Tirzepatide 15 mg ranked in the top three across weight-related parameters, glycemic profile (glycated hemoglobin), lipid parameters (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides), and blood pressure. Tirzepatide 15 mg had the highest efficacy compared with placebo for achieving ≥15% weight loss (risk ratio 10.24, 95% CI: 6.42-16.34). As compared to placebo, tirzepatide and GLP-1 RA across all doses had significant increases in gastrointestinal adverse effects.
CONCLUSIONS
The superiority of tirzepatide and GLP-1 RA in inducing weight loss and their ability to target multiple metabolic parameters render them promising candidates in the treatment of patients with overweight and obesity.
Additional Info
Disclosure statements are available on the authors' profiles:
Efficacy and safety of tirzepatide, GLP-1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta-analysis
Obesity 2024 Feb 27;[EPub Ahead of Print], XH Pan, B Tan, YH Chin, ECZ Lee, G Kong, B Chong, M Kueh, CM Khoo, A Mehta, P Majety, GR Grandhi, GK Dimitriadis, R Foo, NWS Chew, CW Le Roux, MA Mamas, MY ChanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.